MelanomaBRAF V600 Clinical Trials
BRAF V600E/K mutations are present in approximately 40–50% of cutaneous melanoma and define the most targetable subgroup. Dabrafenib plus trametinib and encorafenib plus binimetinib are FDA-approved BRAF/MEK inhibitor combinations with high response rates. Trials investigate BRAF/MEK inhibitors combined with PD-1 checkpoint therapy for durable benefit, triple combinations targeting ERK/PI3K co-escape pathways, and adjuvant targeted therapy strategies.
Top recruiting BRAF V600 Melanoma trials
Ranked by phase and US site count. See all 18 trials matched to your profile →
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
Cancer Research UK
Immunotherapy or Targeted Therapy With or Without Stereotactic Radiosurgery for Patients With Brain Metastases From Melanoma or Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
SWOG Cancer Research Network
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Georgiamune Inc
Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases
M.D. Anderson Cancer Center
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
University of Louisville
Browse other molecular targets with active Melanoma trials.